Alloy Therapeutics

Alloy Therapeutics has raised $40 million in a Series E funding round, achieving a valuation of $1 billion. The funding will help expand its AI-powered platform for drug discovery and development. Key investors include 8VC, JIC Venture Growth Investments, and Echo Capital, along with existing supporters like Mubadala Capital and Thiel Capital.

Alloy Therapeutics has raised $40 million in a Series E round, valuing the Boston-based biotech company at $1 billion. The funding will enhance its tech-enabled drug development platform, which integrates AI with laboratory and clinical capabilities. Key investors include 8VC and JIC Venture Growth Investments, alongside returning firms like Mubadala Capital and Founders Fund. Alloy supports over 100 licensed therapeutic programs, with 22 in clinical development, and aims to streamline drug development for virtual biotech firms.